PUBLIC LAW 103-43—JUNE 10, 1993 107 STAT. 137 "(4) With respect to research on women's health, the Coordinating Committee shall assist the Director of the Office in— "(A) identifying the need for such research, and making an estimate each fiscal year of the funds needed to adequately support the research; "(B) identifying needs regarding the coordination of research activities, including intramural and extramural multidisciplinary activities; "(C) supporting the development of methodologies to determine the circumstances in which obtaining data specific to women (including data relating to the age of women and the membership of women in ethnic or racial groups) is an appropriate function of clinical trials of treatments and therapies; "(D) supporting the development and expansion of clinical trials of treatments and therapies for which obtaining such data has been determined to be an appropriate function; and "(E) encouraging the national research institutes to conduct and support such research, including such clinical trials. "(d) ADVISORY COMMITTEE.— "(1) In carrying out subsection (b), the Director of the Office shall establish an advisory committee to be known as the Advisory Committee on Research on Women's Health (in this subsection referred to as the 'Advisory Committee'). "(2) The Advisory Committee shall be composed of no fewer than 12, and not more than 18 individuals, who are not officers or employees of the Federal Government. The Director of the Office shall make appointments to the Advisory Committee from among physicians, practitioners, scientists, and other health professionals, whose clinical practice, research specialization, or professional expertise includes a significant focus on research on women's health. A majority of the members of the Advisory Committee shall be women. "(3) The Director of the Office shall serve as the chair of the Advisory Committee. "(4) The Advisory Committee shall— "(A) advise the Director of the Office on appropriate research activities to be undertaken by the national research institutes with respect to— "(i) research on women's health; "(ii) research on gender differences in clinical drug trials, including responses to pharmacological drugs; "(iii) research on gender differences in disease etiology, course, and treatment; "(iv) research on obstetrical and gynecological health conditions, diseases, and treatments; and "(v) research on women's health conditions which require a multidisciplinary approach; "(B) report to the Director of the Office on such research; "(C) provide recommendations to such Director regarding activities of the Office (including recommendations on the development of the methodologies described in subsection (c)(4)(C) and recommendations on priorities in carrying out research described in subparagraph (A)); and
�
